FDA Brief

Warning letters Food

FDA warning letter to

ByPro Nutrition LLC

High riskIssued Apr 4, 2023Posted Apr 18, 2023Division of Human and Animal Food Operations West II

FDA warned ByPro Nutrition that its supplement Dodecin is an unapproved and misbranded drug because of pain and disease claims.

What happened

FDA inspected ByPro Nutrition's Columbia, Missouri facility from August 10 to August 17, 2022, then reviewed the Dodecin product label and the website www.bypronutrition.com in October and November 2022 and again in March 2023. FDA found label, website and YouTube claims that Dodecin relieves pain and treats conditions such as arthritis, osteoarthritis, neuropathy, lupus and fibromyalgia, plus customer testimonials repeating those claims. FDA said these claims make Dodecin a drug intended to treat disease, sold without drug approval and without adequate directions for use.

What FDA found

  1. Label and website claims that Dodecin treats pain, arthritis, lupus, nerve pain and other conditions make it a drug intended to cure or prevent disease.

    Section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]
  2. Dodecin is not generally recognized as safe and effective for those uses, so it is a new drug sold without FDA approval.

    Sections 201(p), 301(d) and 505(a) of the Act [21 U.S.C. 321(p), 331(d), 355(a)]
  3. The product is intended for diseases a person cannot diagnose or treat alone, so it cannot carry adequate directions for safe use by a layperson and is misbranded.

    Section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. Shipping the misbranded drug in interstate commerce is prohibited.

    Section 301(a) of the Act [21 U.S.C. 331(a)]

What FDA wants

ByPro Nutrition must write to FDA within 15 working days describing the specific steps taken to fix the violations, how it will prevent them from recurring, and copies of related documents; if fixes cannot be finished in that time, it must explain the delay and when they will be done. The response goes to Compliance Officer Andrew A. Hoopes in Lenexa, Kansas.

Who should pay attention

  • supplement brands that describe products as relieving pain or disease
  • online sellers whose websites and testimonials carry health claims
  • contract manufacturers and label reviewers for dietary supplements

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk